article thumbnail

FTC Issues Interim Report on Ongoing Study of Pharmacy Benefit Managers

Big Molecule Watch

The FTC asserts that “PBMs exert substantial influence over independent pharmacies” and “oversee critical decisions about access to and affordability of medications without transparency or accountability to the public.” Humana Pharmacy Solutions, Inc.; pharmacies in 2023, demonstrating this horizontal consolidation.

article thumbnail

How Prescribing Software is Taking the Pharmacy Industry by Storm

pharmacy mentor

Compliance and Regulatory Adherence Pharmacies operate in a highly regulated environment, and compliance with various laws and guidelines is paramount. UPW helps pharmacies adhere to these regulations by automating many of the compliance-related tasks.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

NHC Comments on Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 – 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027

Putting Patients First Blog

As CMS works to achieve this balance, the NHC would like to emphasize several limitations associated clinical guidelines : Off-Label Usage: Clinical guidelines typically do not cover off-label uses of medications, which can be significant for many patient populations, especially those with rare or complex conditions. Blendon, R.,

article thumbnail

NHC Submits Comments on CMS Draft Guidance for IPAY 2028

Putting Patients First Blog

This step would ensure that real-world considerations, such as off-label uses and quality-of-life impacts, are factored into revised pricing decisions. A minimum 60-day window for public input should be established, with outreach to affected patient groups. McLoughlin et al., 10 Julie A. Patterson, Hanke Zheng, and Jon D.

article thumbnail

Donanemab-Azbt Receives FDA Label Update With New Dosing for Alzheimer Disease

Pharmacy Times

The FDA has approved an updated label with a new recommended titration dosing schedule for donanemab-azbt (Kisunla; Eli Lilly and Company) for once-monthly amyloid-targeting therapy for adults that experience early symptomatic Alzheimer disease (AD). million individuals in the United States aged 65 and older. 3 REFERENCES 1. News release.

article thumbnail

PBMs <3 Counterfeit Drugs

Ramblings of a pharmacist

To all external observers, the medication looked legitimate – it bore a normal label, it was the right size, the product tracing documentation was received in good order. Biktarvy® and other HIV drugs are generally labeled to “dispense in original packaging” so the pharmacist never broke the seal on the bottle.